Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Contact
3rd floor, Block G19, No.1 Yaocheng Avenue
Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
592
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,793.64 | 35.65 | -0.46% |
| DAX 40 | 24,059.83 | 195.48 | -0.81% |
| Dow JONES (US) | 44,434.73 | 63.22 | 0.14% |
| FTSE 100 | 8,981.62 | 40.50 | 0.45% |
| HKSE | 24,203.32 | 63.75 | 0.26% |
| NASDAQ | 20,544.90 | 40.62 | -0.20% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,251.73 | 8.02 | -0.13% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |